At 8.1% CAGR, the APAC Intravenous Immunoglobulin Market is projected to be worth US$ 4,156.85 million by 2028, says Business Market Insights 

According to Business Market Insights' research, the APAC intravenous immunoglobulin market was valued at US$ 2,609.61 million in 2022 and is expected to reach US$ 4,156.85 million by 2028, registering a CAGR of 8.1% from 2022 to 2028. Growing pharmaceutical industry and strong pipeline candidates for IVIG are the critical factors attributed to the market expansion. 

As per the India Brand Equity Foundation (IBEF), India is a major and rising player in the global pharmaceuticals industry. The country is the world's largest trader of generic medications, accounting for about 20% of the worldwide supply by volume. It supplies around 60% of the global vaccination demand. The Indian pharmaceutical industry is worth US$ 42 billion and ranks 3rd in terms of volume and 13th in terms of value across the world. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare (MHLW)'s Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$107 billion. Thus, the growing pharmaceutical industry across the world is likely to create lucrative growth opportunities for the intravenous immunoglobulin market in the coming years. 

On the contrary, adverse effects of immunoglobulin therapy hurdles the growth of APAC intravenous immunoglobulin market. 

Based on type, the APAC intravenous immunoglobulin market is segmented into IgG, IgM, IgA, IgE, and IgD. The IgG segment held 28.8% market share in 2022, amassing US$ 751.81 million. It is projected to garner US$ 1,189.50 million by 2028 to expand at 7.9% CAGR during 2022-2028. 

Based on application, the APAC intravenous immunoglobulin market is segmented hypogammaglobulinemia, chronic inflammatory demyelinating polyneuropathy (CIDP), immunodeficiency diseases, myasthenia gravis (MG), multifocal motor neuropathy (MMN), idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency (SDA), Guillain-Barre syndrome (GBS), and others. The immunodeficiency diseases segment held 21.6% market share in 2022, amassing US$ 563.38 million. It is projected to garner US$ 926.52 million by 2028 to expand at 8.6% CAGR during 2022-2028.

Based on distribution channel, the APAC intravenous immunoglobulin market is segmented into hospital pharmacy, retail pharmacy, and others. The hospital pharmacy segment held 55.4% market share in 2022, amassing US$ 1,446.64 million. It is projected to garner US$ 2,286.53 million by 2028 to expand at 7.9% CAGR during 2022-2028.

Based on end user, the APAC intravenous immunoglobulin market is segmented into hospitals, specialty clinics, and others. The beverages segment held 47.5% market share in 2022, amassing US$ 1,239.54 million. It is projected to garner US$ 1,944.34 million by 2028 to expand at 7.8% CAGR during 2022-2028.

Based on country, the APAC intravenous immunoglobulin market is segmented into China, Japan, India, Australia, South Korea, and Rest of APAC. Our regional analysis states that China captured 28.1% market share in 2022. It was assessed at US$ 734.24 million in 2022 and is likely to hit US$ 1,198.33 million by 2028, exhibiting a CAGR of 8.5% during the forecast period. 

Key players dominating the APAC intravenous immunoglobulin market are ADMA Biologics, Inc.; Bio Products Laboratory Ltd.; CSL Behring (CSL Limited); Grifols, S.A.; Kedrion S.p.A; Octapharma AG; Pfizer Inc.; Prothya Biosolutions B.V.; Shanghai RAAS; and Takeda Pharmaceutical Company Limited among others. 

In 2022, BPL and Atlantic Research Group entered into long-term collaboration. This agreement establishes ARG as BPL's preferred contract research organization (CRO) for conducting clinical research trials and providing supportive services for the company's global new product development programs. The agreement builds on BPL and ARG's previous successful collaboration on clinical trial programs. In 2021, Grifols began a clinical trial in Spain to evaluate the safety and efficacy of a new COVID-19 drug 

Based on the Grifols immunoglobulin Gamunex-C and containing anti-SARS-CoV-2 polyclonal antibodies from plasma donors who have recovered from the disease. 

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com